Premenstrual disorders: Premenstrual syndrome and premenstrual dysphoric disorder

J Obstet Gynaecol Res. 2023 Feb;49(2):510-518. doi: 10.1111/jog.15484. Epub 2022 Nov 1.

Abstract

Recently, the term premenstrual disorders (PMDs), which includes premenstrual syndrome and premenstrual dysphoric disorder as a continuum, has been proposed. Although the precise etiology of PMDs remains unknown, the involvement of hormonal fluctuations is clear. The brain transmitters, serotonin and γ-amino butyric acid, also seem to be involved. Serotonin reuptake inhibitors and oral contraceptives are the current mainstay of treatment, but these are insufficient. Even the currently used prospective two-period symptom diary is not widely used in actual clinical practice, creating a major problem of discrepancy between research and clinical practice. In this review, I would like to outline the latest information and problems in the etiology, diagnosis, and treatment of PMDs, with an emphasis on promising new therapies.

Keywords: PMDD; PMDs; PMS; allopregnolone; serotonin.

Publication types

  • Review

MeSH terms

  • Contraceptives, Oral
  • Female
  • Humans
  • Premenstrual Dysphoric Disorder* / complications
  • Premenstrual Dysphoric Disorder* / diagnosis
  • Premenstrual Dysphoric Disorder* / therapy
  • Premenstrual Syndrome* / drug therapy
  • Premenstrual Syndrome* / therapy
  • Prospective Studies
  • Selective Serotonin Reuptake Inhibitors / therapeutic use

Substances

  • Contraceptives, Oral
  • Selective Serotonin Reuptake Inhibitors